Member Info for Sharpey

Kortisin - Best to ignore comments like Sydneysidline's. Don't feed the 🧌

I'm holding too but I expect a drop today with the best case scenario treading water!

Nothing concrete though. I don't expect 🎆here today!

I put in a 300k sell order with a 3.1p limit at 8:12am this morning. Still hasn't been dealt. Now up to 3.15 buy. Such greedy ba*t*ards!!!

FOMO kicking in now. People don't want to potentially miss out on a big rise tomorrow on the back of the investor presentation.

I did say a few days ago that this would tread water until Thursday.

“There are no global statistics available for the annual diagnosis of relapsed/refractory acute myeloid leukaemia (R/R AML) specifically. However, a study analyzing the global burden of all AML from 1990 to 2021 showed a significant increase, with 144,645 new cases diagnosed worldwide in 2021. Estimates for the United States alone in 2025 predict 22,010 new AML cases, but these figures encompass all AML diagnoses, not just R/R cases.

The average drug costs for relapsed/refractory (R/R) adult AML in the US vary significantly, but a 2019 study found the mean outpatient pharmacy cost to be approximately $24,640 to $30,909 per patient episode, while another analysis reported a median total adjusted direct cost of $116,384 per episode, with pharmacy costs as a component. Newer targeted therapies like enasidenib can cost around $120,131 per course, highlighting the wide range depending on the specific drugs used, with hospitalization and supportive care being major cost drivers overall.”

So even if about 1/3 of patients worldwide use the new product that's about 50,000 treatments. Even if they charge half what enasidenib costs in the US, US$60k, that's US$3bn in revenue.

Now I don't know how much it costs to produce the new drug but that must be considerably lower than US$60k. Say US$20k as a guess. That's US$2bn profit a year. Yet current mcap is just under £78m. R&D costs have been raised so I've ignored these.

Even if I’m 90% out you’re looking at a profit of US$200m with share price of £274.28 (£147.95m profit, mcap £1.47bn = 10 P/E ratio). BTW a typical or "normal" P/E ratio for major pharmaceutical companies is around 20 to 25.

Conclusion, there’s huge upside here even after the 700% rise since end of August!

Last hour full of people with FOMO! 🤣🤣🤣

They'll always be someone willing to sell at these low levels. Most likely people sitting on 200 or 300% profit etc. And if that's what they want to do fair enough. But there's only so many of these people. Once they've sold then it'll motor because the supply will be low.

...are the real criminals. Nearly 15% spread. What a 🃏!!!

I expect treading water until the investor call on Thursday.

Now in profit - break even is 2.97p.

Been holding this for about a year and topped up at low levels to get my BE down. I will top slice at 8p.

DYOR, GLA!

...shows you need to exit these stocks at the right time. Peaked at £6.225 on 20 June. Now 97.5p!

Agreed Dusty. Also ridiculous spread of 12.5% again!!!

If a big miner bid £1 a share I'd be happy to vote yes to the takeover!

Really interesting article - https://www.thetimes.com/business-money/energy/article/monumental-merger-of-anglo-and-teck-could-yield-a-copper-bonanza-mw7bn5sd7

Behind a paywall, but key lines for me:

"Experts say there is one particular factor adding impetus to mining M&A: the scramble for copper, the red metal used in electrical wiring and crucial for the global transition to green energy." And

"The big overarching factor in all of this is people have been looking to get more exposure to copper and it's quite hard to find many new projects," says Richard Marwood, head of UK and European equities at Royal London Asset Management (RLAM), a shareholder in Anglo, Rio and Glencore."

I still think we'll eventually be bought out by a big miner!

...of over 8p soon!

https://m.youtube.com/watch?v=P0uekGdFjHM

So we could see 14p soon according to that chart prediction. I'll take that!!!

There's now a price on OTC. No trades yet though.

https://www.otcmarkets.com/stock/HASTF/overview

"Given the current short-term trend, the stock is expected to rise 86.66% during the next 3 months and, with a 90% probability hold a price between 7.30p and 16.43p at the end of this 3-month period."

https://stockinvest.us/stock/HAMA.L